-
Dec 9, 2024 | 
cancernetwork.com | Ahmad A Tarhini |Hussein Tawbi
Dual Immunotherapy IO Treatment and Sequencing Decisions for Melanoma Panelists discuss how dual immunotherapy for melanoma, including combinations like nivolumab plus ipilimumab or nivolumab plus relatlimab, requires careful consideration of sequencing decisions based on factors such as tumor burden, patient health status, and potential toxicity profiles.
-
Dec 9, 2024 | 
cancernetwork.com | Ahmad A Tarhini |Hussein Tawbi
Indirect Treatment Comparison: RELATIVITY-047 and CheckMate 067Panelists discuss how the indirect treatment comparison of RELATIVITY-047 and CheckMate 067 suggests that nivolumab plus relatlimab may provide similar efficacy to nivolumab plus ipilimumab in advanced melanoma, with a potentially better safety profile.
-
Dec 2, 2024 | 
cancernetwork.com | Ahmad A Tarhini |Hussein Tawbi
2 Commerce Drive Cranbury, NJ 08512
-
Dec 2, 2024 | 
cancernetwork.com | Ahmad A Tarhini |Hussein Tawbi
Key Takeaways from the RELATIVITY-047 Trial: Managing Advanced MelanomaPanelists discuss how the RELATIVITY-047 trial data highlights the efficacy of nivolumab plus relatlimab in managing advanced melanoma, offering improved progression-free survival with a favorable safety profile compared to with nivolumab alone.
-
Jul 4, 2024 | 
nature.com | Sang T. Kim |Sattva Neelapu |Amishi Y. Shah |Matthew Campbell |don gibbons |Tina Cascone | +10 more
Correction to: Nature Communications https://doi.org/10.1038/s41467-022-29539-3, published online 12 April 2022In this article the funding information for Jordan Kramer was omitted and should have read, ‘J.K. is supported by the CPRIT Research Training Award CPRIT Training Program (RP210028)’. The original article has been corrected.
-
Jun 17, 2024 | 
onclive.com | Hussein Tawbi
Nivolumab Plus Relatlimab vs Nivolumab in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY-047): Overall Survival and Melanoma-Specific Survival Outcomes at 3 YearsA 3 year survival update on the RELATIVITY-047 trial (NCT03470922), a global, randomized, double-blind phase 2/3 study comparing nivolumab plus relatlimab vs nivolumab in previously untreated metastatic or unresectable stage III or IV melanoma.
-
Dec 14, 2023 | 
sciencedirect.com | Reinhard Dummer |Hussein Tawbi
• None Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation • None Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study • None The abscopal effect of stereotactic...
-
Oct 25, 2023 | 
targetedonc.com | Hussein Tawbi
During a Targeted Oncology™ Case-Based Roundtable™ event, Hussein A. Tawbi, MD, PhD, and participants discussed which first-line therapy they would recommend for a 78-year-old patient with metastatic melanoma and no BRAF-activating mutation. This is the first of 2 articles based on this event.
-
Oct 18, 2023 | 
targetedonc.com | Hussein Tawbi
Hussein Tawbi, MD, PhD, details the incidence rate of melanoma and that appropriate diagnosis includes an MRI to check for brain metastases and molecular testing for BRAF mutations.
-
Oct 18, 2023 | 
targetedonc.com | Hussein Tawbi
Positive objective response results were demonstrated in the first stage of the phase 2 SCOPE trial. Now, 27 additional patients with advanced melanoma will be treated with SCIB1 and checkpoint inhibitors in stage 2.
